BriaCell Therapeutics (BCT.TO) has opened the first Canadian site for its Phase 3 clinical trial in metastatic breast cancer at Sunnybrook Hospital in Toronto.
The Phase 3 trial is comparing BriaCell's lead candidate Bria-IMT plus an immune checkpoint inhibitor, with physician's treatment of choice for patients with advanced metastatic breast cancer. Overall survival is the primary endpoint, a statement said.
BriaCell's Phase 3 study has over 80 active clinical sites across 15 states in the US.
Price: $5.32, Change: $-0.20, Percent Change: -3.62%